In 2023, the sales of systemic hormonal preparations (excluding sex hormones and insulins) in Italy stood at 557.5 million USD. From 2024 onwards, the forecasted data indicates a steady decline in sales, with the market expected to reach 548.8 million USD by 2028. This reflects a modest annual contraction, with specific year-on-year reductions being: -0.36% in 2025, -0.29% in 2026, -0.25% in 2027, and -0.22% in 2028. The compound annual growth rate (CAGR) over the forecasted period is -0.31%.

Future trends to watch for:

The impact of new therapies and technological advancements on demand.
Government policies and healthcare budget allocations influencing market dynamics.
The evolution of patient demographics, particularly aging populations and their specific hormonal therapy needs.
Potential shifts in global supply chain efficiencies affecting product availability.